title: Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines.
abstract: Tissue inhibitor of metalloproteinase 2 (TIMP-2) is required for the membrane type 1 matrix metalloproteinase (MT1-MMP)-dependent activation of pro-MMP-2 on the cell surface. MT1-MMP-bound TIMP-2 has been shown to function as a receptor for secreted pro-MMP-2, resulting in the formation of a trimolecular complex. In the presence of uncomplexed active MT1-MMP, the prodomain of cell surface-associated MMP-2 is cleaved, and activated MMP-2 is released. However, the behavior of MT1-MMP-bound TIMP-2 during MMP-2 activation is currently unknown. In this study, (125)I-labeled recombinant TIMP-2 ((125)I-rTIMP-2) was used to investigate the fate of TIMP-2 during pro-MMP-2 activation by HT1080 and transfected A2058 cells. HT1080 and A2058 cells transfected with MT1-MMP cDNA (but not vector-transfected A2058 cells) were able to bind (125)I-rTIMP-2, to activate pro-MMP-2, and to process MT1-MMP into an inactive 43-kDa form. Under these conditions, (125)I-rTIMP-2 bound to the cell surface was rapidly internalized and degraded in intracellular organelles through a bafilomycin A(1)-sensitive mechanism, and (125)I-bearing low molecular mass fragment(s) were released in the culture medium. These different processes were inhibited by hydroxamic acid-based synthetic MMP inhibitors and rTIMP-2, but not by rTIMP-1 or cysteine, serine, or aspartic proteinase inhibitors. These results support the concept that the MT1-MMP-dependent internalization and degradation of TIMP-2 by some tumor cells might be involved in the regulation of pericellular proteolysis.
authors.affiliation: Laboratory of Tumor and Development Biology, University of Liège, Tour de Pathologie (B23), Sart Tilman, B-4000 Liège, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Maquoi
authors.forename: F
authors.initials: F
authors.lastname: Frankenne
authors.forename: E
authors.initials: E
authors.lastname: Baramova
authors.forename: C
authors.initials: C
authors.lastname: Munaut
authors.forename: N E
authors.initials: NE
authors.lastname: Sounni
authors.forename: A
authors.initials: A
authors.lastname: Remacle
authors.forename: A
authors.initials: A
authors.lastname: Noël
authors.forename: G
authors.initials: G
authors.lastname: Murphy
authors.forename: J M
authors.initials: JM
authors.lastname: Foidart
mesh_terms: D004789:Enzyme Activation; D006801:Humans; D006863:Hydrogen-Ion Concentration; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D053504:Matrix Metalloproteinases, Membrane-Associated; D008565:Membrane Proteins / Q000378:metabolism; D008666:Metalloendopeptidases / Q000502:physiology*; D009369:Neoplasms / Q000378:metabolism*; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D011994:Recombinant Proteins / Q000378:metabolism; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D008565:Membrane Proteins; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D019716:Tissue Inhibitor of Metalloproteinase-2; C088672:GI 129471; D010649:Phenylalanine; D053504:Matrix Metalloproteinases, Membrane-Associated; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2